Stability and Biological Testing of taurine-conjugated Bile Acid Antioxidant Microcapsules for Diabetes Treatment

Abstract

Aim: Taurine-conjugated bile acids possess positive formulation-stabilization effects, which are desirable in diabetes treatments. The taurine-conjugated bile acid, taurocholic acid (TCA), has shown promising formulation-stabilizing effects on the delivery of the antioxidant drug, probucol (PB), but success is limited due to its poor release profile. This study aimed to design new PB-TCA formulations using new polymers, and examine antioxidant and antidiabetic effects using β-cells for PB with or without TCA. Materials and methods: Different formulations using alginate-insoluble esters of polymethylacrylate polymers encapsulating PB and TCA were developed, microencapsulated and examined for stability and biological activity. Results: TCA addition to new PB matrices improved osmotic and mechanical properties, and this effect was dependent on polymethylacrylate composition and concentration. Conclusion: TCA can optimize the oral delivery of anti-diabetic compounds.

Keywords:

• diabetes mellitus
• eudragit
• microencapsulation
• oral delivery
• probucol
• taurocholic acid

Financial & competing interests disclosure

H Al-Salami has been and is currently receiving of funding from Beijing Nat-Med Biotechnology Co., Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.